

Oliver Fitzgerald Mb Bch Bao, Mrcpi, M

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5557730/publications.pdf>

Version: 2024-02-01

280
papers

18,534
citations

13865

67
h-index

15732

125
g-index

301
all docs

301
docs citations

301
times ranked

16024
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 81-91.	5.6	9
2	Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. <i>Clinical Rheumatology</i> , 2022, 41, 499-511.	2.2	3
3	HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 123-124.	8.0	6
4	Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis. <i>Journal of Rheumatology</i> , 2022, , jrheum.211321.	2.0	1
5	Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2022, , jrheum.211317.	2.0	0
6	GRAPPA 2020 Research Award Recipients. <i>Journal of Rheumatology</i> , 2022, , jrheum.211335.	2.0	0
7	Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2). <i>Rheumatology and Therapy</i> , 2022, 9, 1017-1030.	2.3	11
8	Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects. <i>Journal of Rheumatology</i> , 2022, , jrheum.211320.	2.0	0
9	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. <i>Journal of Rheumatology</i> , 2022, , .	2.0	0
10	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. <i>Arthritis and Rheumatology</i> , 2022, 74, 1535-1543.	5.6	15
11	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.0	182
12	5-year longitudinal study of clinical and patient-reported outcomes in acute anterior uveitis. <i>Eye</i> , 2021, 35, 651-658.	2.1	4
13	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	3.4	43
14	Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110140.	2.7	18
15	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , 2021, 48, 1268-1271.	2.0	4
16	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201675.	2.0	3
17	Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1272-1278.	2.0	2
18	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94.	3.5	9

#	ARTICLE	IF	CITATIONS
19	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201674.	2.0	9
20	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	2.0	2
21	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology</i> , The, 2021, 3, e270-e283.	3.9	19
22	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113
23	Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2021, 8, 723944.	2.6	20
24	Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 817.	1.9	3
25	A multidisciplinary approach to reproductive healthcare in women with rheumatic disease. <i>Irish Journal of Medical Science</i> , 2020, 189, 237-243.	1.5	8
26	Effects of 1-year anti-TNF- α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2020, 39, 167-175.	2.2	50
27	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	2.0	16
28	Advanced musculoskeletal physiotherapy practice: The patient journey and experience. <i>Musculoskeletal Science and Practice</i> , 2020, 45, 102077.	1.3	17
29	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.7	7
30	Cardiovascular Comorbidities in Psoriatic Disease. <i>Rheumatology and Therapy</i> , 2020, 7, 5-17.	2.3	8
31	Applying precision medicine to unmet clinical needs in psoriatic disease. <i>Nature Reviews Rheumatology</i> , 2020, 16, 609-627.	8.0	34
32	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020, 22, 78.	4.7	10
33	Update: Atypical presentation of a midgut neuroendocrine tumor originally diagnosed as eosinophilic fasciitis. <i>Neurology</i> , 2020, 95, 695-697.	1.1	0
34	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020, 7, 553-580.	2.3	54
35	MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 330-336.	4.3	11
36	The many faces of psoriatic arthritis: their genetic determinism. <i>Rheumatology</i> , 2020, 59, i4-i9.	1.9	18

#	ARTICLE	IF	CITATIONS
37	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.9	43
38	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020, 47, 796-808.	2.0	3
39	Bristol rheumatoid arthritis fatigue scale is valid in patients with psoriatic arthritis and is associated with overall severe disease and higher comorbidities. <i>Clinical Rheumatology</i> , 2020, 39, 1851-1858.	2.2	3
40	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. <i>Drug Safety</i> , 2020, 43, 379-392.	3.2	28
41	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1021-1028.	3.0	3
42	Elevated CRP even at the first visit to a rheumatologist is associated with long-term poor outcomes in patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 2951-2961.	2.2	12
43	Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 96, 19-24.	2.0	6
44	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020, 96, 53-57.	2.0	7
45	Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines. <i>Irish Journal of Medical Science</i> , 2019, 188, 169-172.	1.5	11
46	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.9	7
47	Physiotherapist-Led Triage at a Rheumatology-Based Musculoskeletal Assessment Clinic: an 18-Month Service Evaluation of Activity and Outcomes. <i>ACR Open Rheumatology</i> , 2019, 1, 213-218.	2.1	7
48	Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1107-1113.	0.9	18
49	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , 2019, 46, 1089-1096.	2.0	37
50	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
51	AB0440...CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. , 2019, , .		0
52	AB0742...ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
53	SAT0395...RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS. , 2019, , .		1
54	AB0763...SAFETY OF ABATACEPT TREATMENT OVER 2 YEARS IN A PHASE III ACTIVE PSORIATIC ARTHRITIS RANDOMIZED TRIAL (ASTRAEA). , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. <i>Rheumatology</i> , 2019, 58, 144-148.	1.9	24
56	Inflammatory back pain criteria perform well in subset of patients with active axial psoriatic arthritis but not among patients with established axial disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1003-1004.	0.9	12
57	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
58	Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. <i>MAbs</i> , 2019, 11, 116-128.	5.2	70
59	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14
60	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	2.0	7
61	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <i>RMD Open</i> , 2018, 4, e000582.	3.8	34
62	A new era for collaboration?. <i>Rheumatology</i> , 2018, 57, 775-776.	1.9	0
63	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
64	Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 271-294.	6.5	52
65	Remission in psoriatic arthritis—where are we now?. <i>Rheumatology</i> , 2018, 57, 1321-1331.	1.9	16
66	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
67	Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity. <i>Arthritis and Rheumatology</i> , 2018, 70, 396-407.	5.6	42
68	Work Outcomes in Patients Who Stay at Work Despite Musculoskeletal Pain. <i>Journal of Occupational Rehabilitation</i> , 2018, 28, 559-567.	2.2	28
69	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
70	Opportunities and challenges in the treatment of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 440-452.	3.3	11
71	Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?. <i>Rheumatology</i> , 2018, 57, 2053-2055.	1.9	6
72	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 242.	3.5	24

#	ARTICLE	IF	CITATIONS
73	Modifications of Cardiovascular Risk Scores, But Not Standard Risk Scores, Improve Identification of Asymptomatic Coronary Artery Disease in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1329-1330.	2.0	7
74	Advanced musculoskeletal physiotherapy practice in Ireland: A National Survey. <i>Musculoskeletal Care</i> , 2018, 16, 425-432.	1.4	10
75	Advanced practice physiotherapy-led triage in Irish orthopaedic and rheumatology services: national data audit. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 181.	1.9	25
76	Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. <i>Arthritis Research and Therapy</i> , 2018, 20, 73.	3.5	30
77	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
78	GRAPPA 2017 Project Report. <i>Journal of Rheumatology</i> , 2018, 94, 48-51.	2.0	3
79	Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy. <i>Musculoskeletal Care</i> , 2017, 15, 23-35.	1.4	19
80	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
81	Effects of targeted therapies on the bone in arthritides. <i>Autoimmunity Reviews</i> , 2017, 16, 313-320.	5.8	47
82	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
83	GRAPPA 2016 Project Report. <i>Journal of Rheumatology</i> , 2017, 44, 706-710.	2.0	2
84	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1550-1558.	0.9	184
85	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42
86	Early interventions to promote work participation in people with regional musculoskeletal pain: a systematic review and meta-analysis. <i>Clinical Rehabilitation</i> , 2017, 31, 1466-1481.	2.2	13
87	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017, 377, 1537-1550.	27.0	434
88	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1774-1779.	0.9	51
89	A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1445-1452.	2.0	17
90	The Effect of Anterior Uveitis and Previously Undiagnosed Spondyloarthritis: Results from the DUET Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 1347-1354.	2.0	20

#	ARTICLE	IF	CITATIONS
91	Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 158.	3.5	26
92	Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 270-276.	0.8	24
93	Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 155-162.	0.9	100
94	A clinically based protein discovery strategy to identify potential biomarkers of response to anti-IL-17 treatment of psoriatic arthritis. <i>Proteomics - Clinical Applications</i> , 2016, 10, 645-662.	1.6	26
95	Improving recognition of spondyloarthropathy in primary care: an unmet need. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e19-e19.	0.9	0
96	IL-6 blockade in psoriatic arthritis – a new therapeutic option?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 318-319.	8.0	5
97	Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions. <i>Journal of Rheumatology</i> , 2016, 43, 463-464.	2.0	20
98	Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry. <i>Rheumatology</i> , 2016, 55, 891-896.	1.9	16
99	Implications of the diversity of class I HLA associations in psoriatic arthritis. <i>Clinical Immunology</i> , 2016, 172, 29-33.	3.2	19
100	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.0	24
101	Replication of a distinct psoriatic arthritis risk variant at the L23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1417-1418.	0.9	9
102	Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery. <i>Proteomics - Clinical Applications</i> , 2016, 10, 691-698.	1.6	21
103	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016, 43, 979-985.	2.0	3
104	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304.	3.4	119
105	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
106	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter – Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016, 43, 208-213.	2.0	30
107	Psoriatic arthritis: complexities, comorbidities and implications for the clinic. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 405-416.	3.0	33
108	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.9	53

#	ARTICLE	IF	CITATIONS
109	Treatment of psoriatic arthritis. , 2016, , 85-99.		0
110	Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 234-241.	0.9	50
111	Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Research and Therapy, 2015, 17, 115.	3.5	147
112	O53.â€fPTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. Rheumatology, 2015, , .	1.9	1
113	Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Research and Therapy, 2015, 17, 141.	3.5	62
114	Psoriatic Arthritis Under a Proteomic Spotlight: Application of Novel Technologies to Advance Diagnosis and Management. Current Rheumatology Reports, 2015, 17, 35.	4.7	17
115	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 2015, 74, 1882-1885.	0.9	64
116	Enhanced Patient Involvement and the Need to Revise the Core Set â€” Report from the Psoriatic Arthritis Working Group at OMERACT 2014. Journal of Rheumatology, 2015, 42, 2198-2203.	2.0	34
117	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. Journal of Rheumatology, 2015, 42, 1048-1051.	2.0	6
118	Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6Âmonths of TNF inhibitor therapy: a comparative analysis. Clinical Rheumatology, 2015, 34, 1857-1865.	2.2	20
119	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. Journal of Rheumatology, 2015, 42, 1021-1026.	2.0	9
120	A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Annals of the Rheumatic Diseases, 2015, 74, 1990-1995.	0.9	108
121	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	12.8	149
122	Diagnostic delay of more than 6â€...months contributes to poor radiographic and functional outcome in psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1045-1050.	0.9	424
123	Profound reduction in hospital admissions and musculoskeletal surgical procedures for rheumatoid arthritis with concurrent changes in clinical practice (1995-2010). Rheumatology, 2015, 54, 666-671.	1.9	26
124	Peripheral joint involvement in psoriatic arthritis patients. Clinical and Experimental Rheumatology, 2015, 33, S26-30.	0.8	18
125	How Much Is Fatigue Explained by Standard Clinical Characteristics of Disease Activity in Patients With Inflammatory Arthritis? A Longitudinal Study. Arthritis Care and Research, 2014, 66, 1597-1603.	3.4	11
126	Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1206-1211.	2.0	13

#	ARTICLE	IF	CITATIONS
127	Development of a Disease Activity and Responder Index for Psoriatic Arthritis – Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791.	2.0	34
128	GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. <i>Journal of Rheumatology</i> , 2014, 41, 1244-1248.	2.0	5
129	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	3.4	21
130	Editorial: Emerging Evidence for Critical Involvement of the Interleukin-17 Pathway in Both Psoriasis and Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 1077-1080.	5.6	25
131	Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response. <i>Journal of Rheumatology</i> , 2014, 41, 1212-1217.	2.0	85
132	Apremilast: welcome advance in treatment of psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 385-386.	8.0	6
133	Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 371, 1781-1792.	27.0	169
134	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2277-2285.	2.0	51
135	Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 238-242.	0.9	65
136	Inequities in access to biologic and synthetic DMARDs across 46 European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 198-206.	0.9	289
137	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	4.7	34
138	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397
139	High Prevalence of Metabolic Syndrome and of Insulin Resistance in Psoriatic Arthritis is Associated with the Severity of Underlying Disease. <i>Journal of Rheumatology</i> , 2014, 41, 1357-1365.	2.0	135
140	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
141	Tumor Necrosis Factor Inhibition Modulates Thrombospondin-1 Expression in Human Inflammatory Joint Disease through Altered NR4A2 Activity. <i>American Journal of Pathology</i> , 2013, 183, 1243-1257.	3.8	29
142	Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. <i>Rheumatology</i> , 2013, 52, 1572-1582.	1.9	47
143	Th17 and Th22 cells in psoriatic arthritis and psoriasis. <i>Arthritis Research and Therapy</i> , 2013, 15, R136.	3.5	212
144	Exercise and Manual Physiotherapy Arthritis Research Trial (EMPART) for Osteoarthritis of the Hip: A Multicenter Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2013, 94, 302-314.	0.9	84

#	ARTICLE	IF	CITATIONS
145	Periarticular Bone Gain at Proximal Interphalangeal Joints and Changes in Bone Turnover Markers in Response to Tumor Necrosis Factor Inhibitors in Rheumatoid and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 653-662.	2.0	25
146	High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 736-740.	0.9	248
147	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60
148	Variants in <i>RUNX3</i> Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1224-1231.	6.7	63
149	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.9	240
150	Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder. <i>Arthritis Research and Therapy</i> , 2013, 15, R221.	3.5	28
151	Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans. <i>PLoS ONE</i> , 2013, 8, e66456.	2.5	27
152	Interleukin 15 Primes Natural Killer Cells to Kill via NKG2D and cPLA2 and This Pathway Is Active in Psoriatic Arthritis. <i>PLoS ONE</i> , 2013, 8, e76292.	2.5	28
153	Biomarkers of Inflammatory Arthritis and Proteomics. , 2013, , .		0
154	Pulmonary Fibrosis in Systemic Sclerosis. <i>Journal of Thoracic Imaging</i> , 2012, 27, 44-50.	1.5	4
155	GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2196-2197.	2.0	8
156	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1350-1354.	0.9	39
157	Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2189-2192.	2.0	11
158	A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 225-230.	0.9	70
159	Screening for arthritis in patients with psoriasis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 640-641.	8.0	3
160	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 358-362.	0.9	57
161	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 319-326.	0.9	234
162	Investigation of <i>IL1</i> , <i>VEGF</i> , <i>PPARG</i> and <i>MEFV</i> genes in psoriatic arthritis susceptibility: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 313-314.	0.9	15

#	ARTICLE	IF	CITATIONS
163	Pathogenetic Overview of Psoriatic Disease. Journal of rheumatology Supplement, The, 2012, 89, 7-10.	2.2	16
164	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	21.4	848
165	HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis and Rheumatism, 2012, 64, 1134-1144.	6.7	187
166	Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis and Rheumatism, 2012, 64, 1035-1045.	6.7	86
167	Vitamin D Deficiency: Subclinical and Clinical Consequences on Musculoskeletal Health. Current Rheumatology Reports, 2012, 14, 286-293.	4.7	33
168	Vitamin D and its emerging role in immunopathology. Clinical Rheumatology, 2012, 31, 199-202.	2.2	36
169	The Impact of a Revised EQ-5D Population Scoring on Preference-Based Utility Scores in an Inflammatory Arthritis Cohort. Value in Health, 2011, 14, 921-927.	0.3	6
170	Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study. Arthritis Research and Therapy, 2011, 13, R7.	3.5	41
171	Differential Expression of NK Receptors CD94 and NKG2A by T Cells in Rheumatoid Arthritis Patients in Remission Compared to Active Disease. PLoS ONE, 2011, 6, e27182.	2.5	12
172	Responsiveness of physical function outcomes following physiotherapy intervention for osteoarthritis of the knee: an outcome comparison study. Physiotherapy, 2011, 97, 302-308.	0.4	52
173	Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNF α therapy medication. BMC Musculoskeletal Disorders, 2011, 12, 11.	1.9	8
174	Clinical Image: Keratitis in reactive arthritis. Arthritis and Rheumatism, 2011, 63, 2522-2522.	6.7	10
175	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Annals of the Rheumatic Diseases, 2011, 70, 1016-1019.	0.9	68
176	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1641-1644.	0.9	103
177	Composite Measures in Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting. Journal of Rheumatology, 2011, 38, 540-545.	2.0	22
178	Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) - Report of the OMERACT 10 PsA Special Interest Group. Journal of Rheumatology, 2011, 38, 1496-1501.	2.0	35
179	Development of a preliminary composite disease activity index in psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 272-277.	0.9	184
180	Osteoarthritis: 119. The Effectiveness of Exercise Therapy with and without Manual Therapy for Hip Osteoarthritis: A Multicentre Randomised Controlled Trial. Rheumatology, 2011, 50, iii87-iii90.	1.9	0

#	ARTICLE	IF	CITATIONS
181	Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. <i>Rheumatology International</i> , 2010, 30, 1571-1580.	3.0	8
182	Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice. <i>Current Rheumatology Reports</i> , 2010, 12, 264-271.	4.7	4
183	What are the spondyloarthropathies?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 575-577.	3.3	1
184	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. <i>Nature Genetics</i> , 2010, 42, 996-999.	21.4	334
185	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	21.4	918
186	A qualitative study of work participation in early rheumatoid arthritis. <i>International Journal of Therapy and Rehabilitation</i> , 2010, 17, 24-33.	0.3	17
187	Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 706-714.	0.9	39
188	Composite Measures in Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 453-461.	2.0	26
189	Synovial tissue hypoxia and inflammation in vivo. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1389-1395.	0.9	198
190	Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1386-1394.	2.0	114
191	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 448-452.	2.0	18
192	Biomarkers in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 462-467.	2.0	18
193	Acute Serum Amyloid A Induces Migration, Angiogenesis, and Inflammation in Synovial Cells In Vitro and in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model. <i>Journal of Immunology</i> , 2010, 184, 6427-6437.	0.8	92
194	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2199-2203.	0.9	36
195	Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 394-399.	0.9	121
196	Remission in psoriatic arthritis: is it possible and how can it be predicted?. <i>Arthritis Research and Therapy</i> , 2010, 12, R94.	3.5	77
197	Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis. <i>Pharmacoeconomics</i> , 2010, 28, 477-487.	3.3	51
198	Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 401-4.	0.8	18

#	ARTICLE	IF	CITATIONS
199	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. <i>Journal of Rheumatology</i> , 2009, 36, 1792-1799.	2.0	38
200	Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. <i>Journal of Rheumatology</i> , 2009, 36, 1785-1791.	2.0	40
201	Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. <i>Journal of Rheumatology</i> , 2009, 36, 1769-1784.	2.0	21
202	Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers. <i>Journal of Rheumatology</i> , 2009, 36, 1800-1802.	2.0	107
203	Exercise and manual physiotherapy arthritis research trial (EMPART): a multicentre randomised controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 9.	1.9	18
204	Constitutional trisomy 8 and Behçet syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2009, 149A, 982-986.	1.2	26
205	Serum levels of tissue inhibitor of metalloproteinase-1 and periarticular bone loss in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 285-291.	2.2	14
206	Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. <i>Molecular Immunology</i> , 2009, 46, 3345-3357.	2.2	50
207	Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor- α , Oncostatin M and response to biologic therapies. <i>Arthritis Research and Therapy</i> , 2009, 11, R113.	3.5	150
208	Psoriatic arthritis: from pathogenesis to therapy. <i>Arthritis Research and Therapy</i> , 2009, 11, 214.	3.5	110
209	Corticosteroid-associated osteonecrosis of the femoral head: complete resolution on MRI with conservative treatment. <i>BMJ Case Reports</i> , 2009, 2009, bcr0820080673-bcr0820080673.	0.5	0
210	Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry. <i>Clinical Rheumatology</i> , 2008, 27, 763-766.	2.2	7
211	Increased Expression of the Orphan Nuclear Receptor NURR1 in Psoriasis and Modulation following TNF- α Inhibition. <i>Journal of Investigative Dermatology</i> , 2008, 128, 300-310.	0.7	33
212	Biological biomarkers in psoriatic disease. A review. <i>Journal of Rheumatology</i> , 2008, 35, 1443-8.	2.0	20
213	A Role for Type 1 β Corticotropin-Releasing Hormone Receptors in Mediating Local Changes in Chronically Inflamed Tissue. <i>American Journal of Pathology</i> , 2007, 170, 1121-1133.	3.8	15
214	Inpatient and outpatient rehabilitation for patients with rheumatoid arthritis: a clinical and economic assessment. <i>Journal of Medical Economics</i> , 2007, 10, 515-528.	2.1	2
215	Early changes in serum type ii collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. <i>Arthritis and Rheumatism</i> , 2007, 56, 2919-2928.	6.7	45
216	Filaggrin Null Alleles Are Not Associated with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1878-1882.	0.7	41

#	ARTICLE	IF	CITATIONS
217	Immunohistochemistry of the Inflamed Synovium. <i>Methods in Molecular Medicine</i> , 2007, 135, 47-63.	0.8	5
218	Pathogenesis of Psoriatic Arthritis. , 2007, , 48-60.		1
219	Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. <i>Journal of Rheumatology</i> , 2007, 34, 620-2.	2.0	50
220	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1167-70.	2.0	155
221	Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 1003-1012.	1.2	105
222	Psoriatic arthritis: One or more diseases?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 435-450.	3.3	26
223	Spondyloarthropathy: disease at the crossroads of immunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 949-967.	3.3	15
224	Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF- κ B-dependent signal transduction pathway. <i>Arthritis and Rheumatism</i> , 2006, 54, 105-114.	6.7	134
225	Temporal expression pattern of Duffy antigen in rheumatoid arthritis: Up-regulation in early disease. <i>Arthritis and Rheumatism</i> , 2006, 54, 2022-2026.	6.7	17
226	Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1795-1804.	6.7	66
227	Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. <i>Arthritis and Rheumatism</i> , 2006, 54, 3152-3162.	6.7	80
228	Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. <i>European Journal of Immunology</i> , 2005, 35, 1347-1359.	2.9	232
229	Modulation of Orphan Nuclear Receptor NURR1 Expression by Methotrexate in Human Inflammatory Joint Disease Involves Adenosine A2A Receptor-Mediated Responses. <i>Journal of Immunology</i> , 2005, 175, 555-565.	0.8	49
230	Synovial tissue inflammation in early and late osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1263-1267.	0.9	779
231	Psoriatic arthritis synovial histopathology: commentary on the article by Kruthof and colleagues. <i>Arthritis Research</i> , 2005, 7, 124.	2.0	3
232	Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1393-1398.	0.9	67
233	Nucleotide Sequencing of Psoriatic Arthritis Tissue before and during Methotrexate Administration Reveals a Complex Inflammatory T Cell Infiltrate with Very Few Clones Exhibiting Features That Suggest They Drive the Inflammatory Process by Recognizing Autoantigens. <i>Journal of Immunology</i> , 2004, 172, 1935-1944.	0.8	81
234	Tumor necrosis factor- α in psoriasis and psoriatic arthritis: A clinical, genetic, and histopathologic perspective. <i>Current Rheumatology Reports</i> , 2004, 6, 292-298.	4.7	28

#	ARTICLE	IF	CITATIONS
235	Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. <i>Arthritis and Rheumatism</i> , 2004, 50, 1132-1145.	6.7	29
236	Increased synovial tissue NF- κ B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1781-1787.	6.7	77
237	Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1788-1799.	6.7	136
238	Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 3286-3295.	6.7	71
239	Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?. <i>Arthritis Research</i> , 2004, 6, R563.	2.0	54
240	The influence of α 1-acid glycoprotein on collagenase-3 activity in early rheumatoid arthritis. <i>Biomedical Chromatography</i> , 2003, 17, 361-364.	1.7	10
241	Cytokine gene polymorphisms: Association with psoriatic arthritis susceptibility and severity. <i>Arthritis and Rheumatism</i> , 2003, 48, 1408-1413.	6.7	136
242	Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1676-1685.	6.7	108
243	Quality of life, social support, and knowledge of disease in women with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 221-227.	6.7	42
244	Identification of Naf1/ABIN-1 among TNF- α -induced expressed genes in human synoviocytes using oligonucleotide microarrays. <i>FEBS Letters</i> , 2003, 551, 8-12.	2.8	45
245	Inhibition of PGE2 Production by Nimesulide Compared with Diclofenac in the Acutely Inflamed Joint of Patients with Arthritis. <i>Drugs</i> , 2003, 63, 31-36.	10.9	17
246	Suprascapular nerve block (using bupivacaine and methylprednisolone acetate) in chronic shoulder pain. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 400-406.	0.9	129
247	Activation of Nuclear Orphan Receptor NURR1 Transcription by NF- κ B and Cyclic Adenosine 5'-Monophosphate Response Element-Binding Protein in Rheumatoid Arthritis Synovial Tissue. <i>Journal of Immunology</i> , 2002, 168, 2979-2987.	0.8	102
248	Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 726-729.	0.9	67
249	Preliminary observations on the influence of rheumatoid α 1-acid glycoprotein on collagen fibril formation. <i>Biomedical Chromatography</i> , 2002, 16, 332-342.	1.7	13
250	Corticotropin-Releasing Hormone Signaling in Synovial Tissue Vascular Endothelium Is Mediated through the cAMP/CREB Pathway. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 119-130.	3.8	30
251	Disease Mechanisms in psoriasis and psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2001, 3, 419-427.	4.7	8
252	Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 782-793.	6.7	89

#	ARTICLE	IF	CITATIONS
253	Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 1744-1753.	6.7	107
254	Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1? corticotropin-releasing hormone receptor. <i>Arthritis and Rheumatism</i> , 2001, 44, 1761-1767.	6.7	54
255	Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2263-2274.	6.7	120
256	Psoriatic arthritis—“an enthesopathy-based disorder? comment on the article by McGonagle et al. <i>Arthritis and Rheumatism</i> , 2000, 43, 712.	6.7	4
257	Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. <i>Arthritis Research</i> , 2000, 2, 142.	2.0	122
258	Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. <i>Rheumatology</i> , 1999, 38, 34-42.	1.9	97
259	Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 493-499.	0.9	46
260	Tuberculosis of the wrist. <i>Arthritis and Rheumatism</i> , 1999, 42, 2724-2726.	6.7	12
261	Multidisciplinary patient care in rheumatoid arthritis: evolving concepts in nursing practice. <i>Best Practice and Research in Clinical Rheumatology</i> , 1999, 13, 661-674.	3.3	9
262	Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1998, 41, 180-182.	6.7	44
263	Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. <i>Arthritis and Rheumatism</i> , 1998, 41, 663-669.	6.7	110
264	Ultrasound guided injection of recalcitrant plantar fasciitis. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 383-383.	0.9	72
265	Comparison of the accuracy of steroid placement with clinical outcome in patients with shoulder symptoms. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 59-63.	0.9	272
266	Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 1997, 9, 295-301.	4.3	13
267	Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 115-124.	6.7	453
268	Synovial membrane cellularity and vascularity.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 511-515.	0.9	67
269	The Significance of Fat and Muscle Areas in the Lumbar Paraspinal Space. <i>Journal of Computer Assisted Tomography</i> , 1994, 18, 275-278.	0.9	38
270	Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 893-900.	6.7	230

#	ARTICLE	IF	CITATIONS
271	Lymphedema of the upper limb in patients with psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1993, 22, 350-356.	3.4	46
272	Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis. <i>American Journal of Cardiology</i> , 1993, 71, 1337-1340.	1.6	55
273	Synovial vascularity is increased in rheumatoid arthritis: Comment on the article by Stevens et al. <i>Arthritis and Rheumatism</i> , 1992, 35, 1540-1541.	6.7	18
274	Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1991, 50, 792-796.	0.9	108
275	Prospective study of the evolution of Raynaud's phenomenon. <i>American Journal of Medicine</i> , 1988, 84, 718-726.	1.5	74
276	EFFECTS OF JOINT LAVAGE ON KNEE SYNOVITIS IN RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1985, 24, 6-10.	1.9	18
277	Poor long-term results from low-dose methotrexate therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1984, 27, 599-600.	6.7	11
278	Nicotinic acid inhibition of uricase. <i>Irish Journal of Medical Science</i> , 1969, 2, 531-534.	1.5	1
279	Urease in the Gastric Mucosa and its Increase after a Meat Diet, Soya Bean Flour Diet or Urogastrone Injections. <i>Nature</i> , 1946, 158, 305-305.	27.8	22
280	Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. <i>Rheumatology and Therapy</i> , 0, , .	2.3	3